Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | ABHD6 | Q9BV23 | 5/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17469262 | 1.00 | ESR2 (0.46) | ESR2NR1H2ABHD6ADORA1MAPT | |
| SCHEMBL17463408 | 0.89 | ESR2 (0.46) | ESR2NR1H2ABHD6ADORA1MAPT | |
| SCHEMBL15502993 | 0.89 | ESR2 (0.48) | ESR2NR1H2ABHD6ADORA1MAPT | |
| SCHEMBL15506323 | 0.87 | ESR2 (0.46) | ESR2NR1H2ABHD6ADORA1MAPT | |
| SCHEMBL29168627 | 0.86 | ABHD6 (0.42) | ESR2ABHD6MAPTESR1KDM4E | |
| SCHEMBL31013875 | 0.86 | ESR2 (0.52) | ESR2NR1H2ABHD6ADORA1MAPT | |
| SCHEMBL15506349 | 0.86 | ESR2 (0.46) | ESR2NR1H2ABHD6ADORA1MAPT | |
| SCHEMBL15506351 | 0.85 | ESR2 (0.45) | ESR2NR1H2ABHD6ADORA1MAPT | |
| SCHEMBL31014016 | 0.83 | ESR2 (0.49) | ESR2NR1H2ABHD6ADORA1MAPT | |
| SCHEMBL17463403 | 0.82 | ESR2 (0.43) | ESR2NR1H2ADORA1STSGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651955-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-20240293392-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-09-05 | — | — | US | disclosed |
| WO-2024153947-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2024-07-25 | — | — | WO | disclosed |
| CN-117693507-A | Inhibitor compounds | 奈奥芬莱有限公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023002165-A1 | INHIBITOR COMPOUNDS | Neophore Limited (GB) | 2023-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293392-A1 | INHIBITOR COMPOUNDS | MSH2, PMS2, MSH6 | ESR2 568/4885NR1H2 2027/4885ABHD6 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.